首页> 美国卫生研究院文献>Nature Public Health Emergency Collection >Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis
【2h】

Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis

机译:中国心脏病学会专家对成人暴发性心肌炎的诊治共识

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fulminant myocarditis is primarily caused by infection with any number of a variety of viruses. It arises quickly, progresses rapidly, and may lead to severe heart failure or circulatory failure presenting as rapid-onset hypotension and cardiogenic shock, with mortality rates as high as 50%–70%. Most importantly, there are no treatment options, guidelines or an expert consensus statement. Here, we provide the first expert consensus, the Chinese Society of Cardiology Expert Consensus Statement on the Diagnosis and Treatment of Fulminant Myocarditis, based on data from our recent clinical trial ( ). In this statement, we describe the clinical features and diagnostic criteria of fulminant myocarditis, and importantly, for the first time, we describe a new treatment regimen termed life support-based comprehensive treatment regimen. The core content of this treatment regimen includes (i) mechanical life support (applications of mechanical respirators and circulatory support systems, including intraaortic balloon pump and extracorporeal membrane oxygenation, (ii) immunological modulation by using sufficient doses of glucocorticoid, immunoglobulin and (iii) antiviral reagents using neuraminidase inhibitor. The proper application of this treatment regimen may and has helped to save the lives of many patients with fulminant myocarditis.
机译:暴发性心肌炎主要是由多种病毒感染引起的。它发生迅速,进展迅速,并可能导致严重的心力衰竭或循环衰竭,表现为快速发作的低血压和心源性休克,死亡率高达50%–70%。最重要的是,没有治疗选择,指南或专家共识声明。在此,我们根据最近的临床试验数据(),提供了第一个专家共识,即中国心脏病学会关于恶性心肌炎的诊断和治疗专家共识声明。在此声明中,我们描述了暴发性心肌炎的临床特征和诊断标准,重要的是,我们首次首次描述了一种新的治疗方案,称为基于生命支持的综合治疗方案。该治疗方案的核心内容包括:(i)机械生命支持(机械呼吸器和循环支持系统的应用,包括主动脉内球囊泵和体外膜氧合作用;(ii)使用足够剂量的糖皮质激素,免疫球蛋白进行免疫调节,以及(iii)使用神经氨酸酶抑制剂的抗病毒药物该治疗方案的正确应用可能并且已经挽救了许多暴发性心肌炎患者的生命。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号